LogicBio Therapeutics (OTCMKTS:LOGC) Sees Strong Trading Volume – Should You Buy?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) saw an uptick in trading volume on Thursday . 402,240 shares were traded during trading, an increase of 189% from the previous session’s volume of 139,226 shares.The stock last traded at $14.82 and had previously closed at $14.90.

LogicBio Therapeutics Stock Down 0.5%

The company has a quick ratio of 1.24, a current ratio of 1.87 and a debt-to-equity ratio of 0.29. The stock has a market cap of $677.72 million, a price-to-earnings ratio of -20.30 and a beta of 2.11. The stock has a fifty day moving average of $11.11 and a two-hundred day moving average of $9.50.

LogicBio Therapeutics (OTCMKTS:LOGC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The business had revenue of $33.60 million during the quarter, compared to the consensus estimate of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body.

LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder.

Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets.